Thymidylate Synthase Expression in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors

Real time quantitative PCR.

1996 • 6,155 citations

The new World Health Organization classification of lung tumours

2001 • 1,131 citations

Histological Typing of Endocrine Tumours

2000 • 741 citations

Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors.

1995 • 668 citations

Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients With Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas

2004 • 590 citations

Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin.

1997 • 484 citations

Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase

2006 • 364 citations

Gastrinoma (Duodenal and Pancreatic)

2006 • 285 citations

Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression

2004 • 245 citations

Cell cycle regulation of thymidylate synthetase gene expression in cultured mouse fibroblasts.

1980 • 235 citations

Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?

2006 • 231 citations

Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence

2000 • 228 citations

Efficacy and Safety of Prolonged-Release Lanreotide in Patients With Gastrointestinal Neuroendocrine Tumors and Hormone-Related Symptoms

1999 • 219 citations

Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours.

2003 • 215 citations

Investigation of the Prognostic and Predictive Value of Thymidylate Synthase, p53, and Ki-67 in Patients With Locally Advanced Colon Cancer

2002 • 177 citations

5-fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors

1998 • 161 citations

p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site.

1998 • 148 citations

Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil.

1984 • 131 citations

Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer.

2000 • 127 citations

Prognostic importance of thymidylate synthase expression in early breast cancer.

1997 • 123 citations

Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy

2004 • 103 citations

Vascular Endothelial Growth Factor Messenger RNA Expression Level Is Preserved in Liver Metastases Compared with Corresponding Primary Colorectal Cancer

2006 • 98 citations

Neuroendocrine Neoplasia

2000 • 97 citations

Interferon-α and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?

2006 • 94 citations

The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer.

2001 • 90 citations

Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy.

2000 • 85 citations

Thymidylate Synthase Expression and Response to Neoadjuvant Chemotherapy in Patients With Advanced Head and Neck Cancer

1997 • 70 citations

The Enzymatic Synthesis of Thymidylate

1962 • 54 citations

Prognostic significance of thymidylate synthase activity in bladder carcinoma

2001 • 36 citations

Regulation of DNA repair gene expression in human cancer cell lines

2005 • 35 citations

5-FU in the treatment of small cell anaplastic carcinoma of the lung: a phase II trial.

1981 • 9 citations

Phase II trial of continuous/metronomic 5-fluorouracil infusion plus long acting Octreotide in advanced neuroendocrine carcinoma

2007 • 1 citations